AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye.
Crystal Lake, Illinois-based Aptar’s patented Cartridge Pump System (CPS), designed for the multidose delivery of preserved and non-preserved drug formulations, received approval as the device for delivering Oyster Point Pharma’s Tyrvaya (varenicline solution) nasal spray (0.03 mg).
Get the full story at our sister site, Drug Delivery Business News.